Q1 2024 · —
Revenue—
Net Income-$12.51M-$12.51M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$18.94-$18.94 no prior Q1 2023 on fileno prior Q4 2023 on file
Operating Income-$15,374,000—
Operating Cash Flow-$14,587,000—
Free Cash Flowderived-$14,591,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net Income | -$12.51M | -$7.41M |
| EPS Diluted | -$18.94 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR